SWOG clinical trial number
CTSU/R1010

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma

Closed
Phase
Abbreviated Title
Ph III HER-2 Esophageal with Trimodality + Trastuzumab
Status Notes
This study is closed to accrual to STEP 1 effective 11/10/15.
Activated
09/01/2011
Closed
11/10/2015
Participants
CTSU

Research committees

Gastrointestinal Cancer
Symptom Control and Quality of Life

Treatment

Paclitaxel Carboplatin Trastuzumab RT

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

SWOG has endorsed this trial via the Endorsement Plus Option. Therefore, institutions holding dual memberships in SWOG and RTOG may credit either Group for enrollments, provided the credited investigator is a member of the credited Group.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2022

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

H Safran;K Winter;D Ilson;D Wigle;T DiPetrillo;M Haddock;T Hong;L Leichman;L Rajdev;M Resnick;L Kachnic;S Seaward;H Mamon;D Diaz Pardo;C Anderson;X Shen;A Sharma;A Katz;J Salo;K Leonard;J Moughan;C Crane Lancet Oncology Feb;23(2):259-269

PMid: PMID35038433

Other Clinical Trials

SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Research Committee(s)
Symptom Control and Quality of Life
Activated
01/17/2023
Accrual
51%
Open
Phase
SWOG Clinical Trial Number
EAQ202

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase